関連する実験動画

Updated: Jul 16, 2026

Quantifying Single Microvessel Permeability in Isolated Blood-perfused Rat Lung Preparation
07:22

Quantifying Single Microvessel Permeability in Isolated Blood-perfused Rat Lung Preparation

Published on: June 30, 2014

低分子量ヘパリンの皮下投与の生物利用性は,血管圧縮剤を服用している患者に対して

Janine Dörffler-Melly, Evert de Jonge, Anne-Corneliede Pont

    Lancet (London, England)
    |March 19, 2002
    PubMed
    まとめ

    血管圧縮剤を投与している集中治療室 (ICU) の患者は,静脈性血栓栓塞栓症の予防に低分子量ヘパリン (LMWH) の効果が低下していることを示しています. これは,これらの重篤な患者に調整されたLMWH投与または投与の必要性を示唆しています.

    さらに関連する動画

    Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay08:43

    Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

    Published on: June 19, 2018

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

    Published on: June 18, 2020

    関連する概念動画

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...